6 Best Peptides for Peripheral Nerve Injury

What to Know Before Choosing a Peptide for Peripheral Nerve Injury

Peripheral nerve injury is a genuinely difficult target. The peripheral nervous system has some capacity to heal on its own, but recovery is often slow, incomplete, and highly dependent on the severity of the original damage. Neuroinflammation, scar tissue formation, and the loss of the Schwann cells that normally guide regenerating axons back toward their targets can all stall the process. That difficulty is exactly why people investigating this space look beyond conventional options and toward peptides, compounds that can, at least in animal models, nudge the biology toward repair.

Every compound in this guide earned its place because people use it or are actively discussing using it for peripheral nerve injury. That is the whole inclusion test. A peptide does not need FDA approval, a completed randomized controlled trial, or a listing at a US pharmacy to appear here. FDA-approved compounds, telemedicine-prescribed compounds, and research-only compounds are all represented. Where the evidence is thin, that is described honestly inside each entry rather than used as a reason to leave the compound off the list.

One piece of context is worth stating plainly before you reach the entries: no peptide has completed a human clinical trial specifically for peripheral nerve injury as of mid-2026. The field is overwhelmingly preclinical. That does not make these compounds uninteresting or unused. It means the evidence framing in each entry matters, and the honest one to two sentence description of where each compound's evidence actually comes from is doing real work in every entry, not boilerplate hedging.

The compounds are numbered by how prominently each appears in research and real-world use, not ranked as recommendations of one over another. The right compound for any individual depends on their specific injury, their health history, and the guidance of a qualified provider.

1. BPC-157: The Most Studied Compound for Nerve Repair

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice, and it has more published animal data for peripheral nerve repair than any other compound in this space. That preclinical depth is why it sits first on the list and why it is the first compound most people encounter when they start researching recovery from nerve damage.

The reason BPC-157 shows up so consistently in nerve injury research comes down to what it does at the level of cell biology. It activates the VEGF pathway, which triggers the growth of new blood vessels, a process called angiogenesis. More blood vessels reaching damaged nerve tissue means more oxygen and more of the raw materials needed to rebuild. Beyond that vascular mechanism, BPC-157 activates the EGR-1 transcription factor and the MAPK/ERK signaling pathway, both of which regulate cell growth and repair at the gene-expression level. It also reduces neuroinflammation, which matters because secondary inflammatory damage often compounds the original injury, and it appears to limit fibrosis, the scar tissue that can physically block regenerating axons from finding their way back to their targets.

In rodent sciatic nerve transection studies, BPC-157 has consistently produced measurable improvements in axonal regrowth and functional recovery. That animal data is the strongest preclinical foundation on this list for peripheral nerve specifically. The gap is the human side: no published clinical trial has tested BPC-157 in people with peripheral nerve injury as of mid-2026. BPC-157 is classified as a research chemical in the United States and is not FDA-approved for any indication. User reports from community protocols describe meaningful reductions in nerve-related pain and irritation, with some users noting effects within the first week of injectable use near the injury site. Oral administration is also reported, though injectable use closer to the injury is the more common pattern in community protocols.

Safety information comes primarily from animal research, where no lethal dose has been identified and organ toxicity appears minimal. The main caution that recurs in both the literature and community discussions involves BPC-157's angiogenic properties: because it promotes new blood vessel formation, there is a theoretical concern about use in the presence of active cancer. Long-term human safety data does not yet exist, and the unregulated sourcing environment adds its own layer of risk around purity and concentration accuracy.

2. ARA-290: For Neuropathic Pain and Small Fiber Neuropathy

ARA-290, also called cibinetide, is derived from the structure of erythropoietin, the hormone that stimulates red blood cell production. The key engineering decision behind the compound is that it is designed to activate a separate receptor pathway, the innate repair receptor, without triggering erythropoietin's blood-forming effects. That specificity makes it a more targeted tool for the nerve injury context than a straight erythropoietin analog would be.

ARA-290 has undergone more formal clinical investigation than most compounds on this list. The evidence is most developed for two specific subtypes of nerve pathology: small fiber neuropathy and diabetic peripheral neuropathy. In small fiber neuropathy research, ARA-290 has shown the potential to improve intraepidermal nerve fiber density, a measurable marker of peripheral nerve function, alongside reductions in neuropathic pain. That combination of a structural signal and a symptomatic one is a meaningful distinction from compounds that address only pain without any indication of actual nerve repair.

Community experience reinforces the clinical picture, though with an important caveat that runs through nearly every user account. The pain relief ARA-290 produces, which users frequently describe as substantial, tends to fade within one to two weeks of stopping the compound. That pattern points toward symptom management with some regenerative potential rather than a durable one-time repair. Users pursuing what they describe as actual nerve healing report longer protocols, often 90 days or more, rather than the shorter cycles that yield meaningful but temporary pain relief. The combination of ARA-290 with GHK-Cu, a copper peptide with wound-healing and anti-inflammatory properties, appears in community accounts more than any other stack for this goal, with users describing a meaningfully longer relief window from the combination than from either compound used alone.

ARA-290 is not FDA-approved. It has a more developed clinical trial history than BPC-157 for neuropathic conditions, but it remains outside standard medical practice in the United States and is accessed through research channels.

3. Cerebrolysin: For Neurotrophic Support and Remyelination

Cerebrolysin is not a single synthetic compound. It is a preparation derived from porcine brain tissue containing a mixture of low-molecular-weight peptides and free amino acids, several of which function as neurotrophic factors, proteins that support the survival and growth of neurons. That neurotrophic profile is what makes it relevant to peripheral nerve injury, even though its longest clinical track record is in central nervous system conditions like stroke recovery and Alzheimer's disease.

Cerebrolysin is approved in more than 50 countries for neurological conditions, though not in the United States. That international approval history means it carries a longer human safety observation period than any other compound on this list, a relevant point when comparing it to research chemicals with no human trial data at all.

For peripheral nerve injury specifically, the published evidence comes primarily from animal models. In sciatic nerve transection studies, Cerebrolysin has shown improvements in myelin formation, vascularization around the injured nerve, and Schwann cell condition. Schwann cells are the cells that wrap around peripheral nerve axons to form the protective myelin sheath and that guide regenerating axons back toward their targets during recovery. Supporting Schwann cell health is one of the mechanisms through which Cerebrolysin is thought to aid peripheral recovery, and it is a mechanism that sits alongside the general neurotrophic support the preparation delivers.

The translation to human peripheral nerve injury has not been established through large-scale clinical trials. What exists is a strong animal data foundation for PNS-relevant mechanisms and decades of human clinical use for neurological conditions that share real biological overlap with peripheral nerve pathology. Practitioners familiar with the international literature are typically the route to Cerebrolysin access, since the compound is not available at US pharmacies and is administered by injection, most often intramuscularly or intravenously, in clinical settings.

4. TB-500: For Fibrosis Reduction and Repair-Environment Support

TB-500 is a synthetic version of Thymosin Beta-4, a protein that occurs naturally throughout the body and plays a role in cell migration, wound healing, and tissue repair. In the nerve injury context, it rarely appears as a standalone compound. TB-500 shows up most consistently in combination protocols, most often stacked with BPC-157, and its role in those stacks is reasonably clear: it addresses the fibrotic and inflammatory environment that can impede nerve regeneration, while BPC-157 handles the more direct angiogenic and repair-signaling work.

The mechanism relevant to nerve repair centers on TB-500's anti-fibrotic and anti-inflammatory properties. Scar tissue that forms at or near an injury site can physically obstruct regenerating axons. TB-500 appears to reduce that fibrosis. It also supports neurogenesis, the formation of new neurons, and promotes the migration of cells involved in repair processes. Some animal data supports its role in neuropathic and spinal cord injury recovery, though the published evidence specifically for peripheral nerve injury is thinner than what exists for BPC-157 or the neurotrophic compounds on this list.

User-reported experience with TB-500 as a standalone for peripheral nerve injury is limited. The more common pattern in community protocols is pairing it with BPC-157, with users describing faster reductions in back pain and sciatica symptoms within roughly a week of combined use compared to either compound alone. TB-500 is a research chemical in the United States, not FDA-approved for any indication, and is obtained through the same research channels as BPC-157.

5. Semax: For Neurotrophic Signaling Upregulation

Semax is a synthetic analog of ACTH, a hormone produced by the pituitary gland that plays a role in stress response and cortisol regulation. It was developed in Russia, where it is approved for neurological conditions, and it has been studied specifically for its ability to upregulate two of the most important neurotrophic factors in peripheral nerve biology: BDNF, brain-derived neurotrophic factor, and NGF, nerve growth factor. Both are proteins that promote neuron survival, axonal growth, and the ongoing maintenance of peripheral nerve connections.

The evidence for Semax in peripheral nerve injury specifically is modest. Animal studies, particularly those pairing Semax with the anxiolytic peptide Selank, show accelerated nerve regeneration and improved neuromuscular performance compared to untreated controls. The biological logic holds: if injured neurons are struggling to maintain the growth and survival signals they need, compounds that upregulate BDNF and NGF can support that signaling environment. Whether that animal model finding translates meaningfully to peripheral nerve repair in humans has not been tested in controlled trials.

In community protocols, Semax is frequently paired with BPC-157 rather than used alone, described as providing neurotrophic signaling support that BPC-157's more mechanical angiogenic and anti-fibrotic approach does not directly address. Administration is typically intranasal, which sets Semax apart from the injectable compounds elsewhere on this list and makes it the most accessible route-of-administration option for people who prefer non-injectable delivery. Semax is not FDA-approved in the United States and is available through research channels.

6. Cortagen: For Neuroprotective Support in Neurological Protocols

Cortagen is a tetrapeptide, a chain of four amino acids, developed in Russia within a research tradition focused on short regulatory peptides for organ and tissue support. It belongs to the same peptide bioregulator class studied by Russian institutions over several decades, with the broader goal of maintaining nervous system function and slowing age-related decline in neural tissue.

The evidence base for Cortagen is the thinnest of any compound on this list, and that should be stated plainly upfront. No human clinical trial data has been published for Cortagen in peripheral nerve injury as of 2026. What exists is primarily preclinical data from Eastern European research literature, which has not been widely replicated or validated in Western peer-reviewed journals, along with the broader mechanistic framework for the short regulatory peptide class. Peptides in this class are understood to influence gene expression and protein synthesis at the cellular level, and some neuroprotective activity has been attributed to Cortagen in that preclinical context.

Cortagen appears in discussions of peripheral nerve injury recovery primarily within communities familiar with Russian peptide bioregulator research, often mentioned alongside Cerebrolysin and Semax as part of a broader neurologically-focused protocol. Its inclusion here reflects that genuine pattern of discussion and use. If you are evaluating compounds in this space with an eye toward evidence quality, Cortagen is the entry on this list where the evidence gap is largest, and the basis for inclusion is community-reported interest and preclinical framework rather than controlled research data.

How These Peptides Compare

Frequently Asked Questions

Are Any of These Peptides FDA-Approved for Nerve Injury?

None of the peptides covered in this guide are FDA-approved specifically for peripheral nerve injury. No peptide has completed a human clinical trial specifically for this indication as of mid-2026. Cerebrolysin holds approval in more than 50 countries for neurological conditions but is not approved or commercially available in the United States. ARA-290 has the most developed clinical research record among the compounds here, with human studies focused on small fiber neuropathy and diabetic neuropathic pain, but it has not received FDA approval for any indication.

Is the Evidence Strong Enough to Take These Compounds Seriously?

The honest answer depends on which compound you are evaluating and what kind of evidence you find meaningful. BPC-157 has a genuinely substantial preclinical foundation, with more published rodent nerve transection data than any other compound in this space, but zero published human trials for nerve injury. ARA-290 and Cerebrolysin carry the strongest human-adjacent evidence, one through formal clinical investigation for neuropathic conditions and the other through decades of approved international clinical use in neurological settings. Cortagen sits at the far end of that spectrum, where the available evidence is thin preclinical data and community-reported interest rather than controlled research. Understanding where each compound falls is what makes a guide like this useful rather than misleading.

How Long Does Recovery Typically Take with Peptide Protocols for Nerve Injury?

There is no established clinical timeline for peptides in peripheral nerve injury because no controlled human trials have been completed for this specific indication. Community-reported experience suggests that symptom relief, particularly with compounds like ARA-290, can appear within days to a few weeks, but effects in the pain-relief category often fade after stopping. Users describing meaningful progress toward nerve repair rather than temporary symptom relief typically report protocols lasting 90 days or longer. Anyone pursuing peptides for a nerve injury should be working with a qualified healthcare provider given the severity of the condition and the absence of formal clinical guidance.

Can These Peptides Be Combined?

Combining compounds is common in community protocols for peripheral nerve injury. The BPC-157 and TB-500 stack is the most frequently reported combination, with users describing the two as addressing complementary aspects of the repair environment: BPC-157 on the angiogenic and repair-signaling side, TB-500 on fibrosis reduction and broader tissue repair support. ARA-290 combined with GHK-Cu also appears regularly in accounts from people managing neuropathic pain from small fiber neuropathy. The published evidence for combination protocols is no stronger than the evidence for individual compounds here, and the safety of specific combinations has not been studied in controlled human research.

Do These Peptides Require a Prescription?

Most compounds on this list are not available through standard prescription channels in the United States. BPC-157, TB-500, Semax, and Cortagen are research chemicals that are not FDA-approved for any indication and are not legally prescribed by US physicians for nerve injury. ARA-290 occupies a similar position despite its more developed clinical research history. Cerebrolysin requires a prescription in the countries where it is approved and is sometimes accessed through international medical settings or specialty clinics with international sourcing. Some functional medicine and regenerative medicine practitioners work with these compounds off-label, so the practical path to access varies by practitioner and region.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and user-reported real-world use of peptides for peripheral nerve injury in one place.